Aromatic-Cationic Peptides for Dominant Optic Atrophy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Leber's hereditary optic neuropathy (LHON) and dominant optic atrophy (DOA) lack effective prevention and therapeutic options, with existing strategies showing limited success in reversing optic neuropathy and visual loss once it occurs.
Innovation Solution
Administration of therapeutically effective amounts of aromatic-cationic peptides, such as D-Arg-2′,6′-dimethyltyrosine-Lys-Phe-NH2, which are water-soluble, penetrate cell membranes, and can be formulated for various administration routes including intraocular, topical, and iontophoretic delivery, potentially offering synergistic effects when combined with additional active agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for LHON and DOA, then existing therapeutic options are maintained, but they show limited success in reversing optic neuropathy and visual loss
Solution Approach 1:
The patent introduces aromatic-cationic peptides with specific molecular characteristics (positive charge, aromatic groups, specific amino acid composition) that differ from conventional treatments. These parameter changes in the therapeutic agent enable improved penetration of cell membranes and mitochondria, thereby enhancing efficacy in reversing optic neuropathy and visual loss where conventional treatments have shown limited success
2Reliability
If aromatic-cationic peptides are administered, then potential for ameliorating physiological effects of DOA and LHON is improved, but further clinical trials are necessary to fully establish efficacy
Solution Approach 1:
The patent performs preliminary in vitro and in vivo studies to demonstrate the therapeutic potential of aromatic-cationic peptides before full clinical implementation. These preliminary actions include showing penetration of cell and organellar membranes, protection against mitochondrial dysfunction, and amelioration of physiological effects in model systems, thereby establishing a foundation for future clinical trials
3Ease of operation
If aromatic-cationic peptides are used, then water solubility and cell membrane penetration are improved, but formulation complexity for various administration routes increases
Solution Approach 1:
The aromatic-cationic peptides are designed with specific molecular parameters (positive charge, aromatic groups, specific amino acid sequence) that inherently provide water solubility and cell membrane penetration capabilities. This parameter optimization reduces the need for complex formulation strategies while maintaining ease of administration through various routes including intraocular, topical, and iontophoretic delivery
Data Source
AI summary
The disclosure generally describes methods of preventing or treating dominant optic atrophy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates generally to the treatment or prevention of Leber's hereditary optic neuropathy (LHON) or dominant optic atrophy (DOA) in mammals through administration of therapeutically effective amounts of aromatic-cationic peptides to subjects in need thereof. In one aspect, the present disclosure provides a method of treating or preventing dominant optic atrophy in a mammalian subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide.